Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

Ailawadhi S, Kelly KR, Vescio RA, Jagannath S, Wolf J, Gharibo M, Sher T, Bojanini L, Kirby M, Chanan-Khan A.

Clin Lymphoma Myeloma Leuk. 2018 Sep 5. pii: S2152-2650(18)31122-4. doi: 10.1016/j.clml.2018.08.018. [Epub ahead of print]

PMID:
30340993
2.

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, Jiang L, Roy V, Witzig TE, Ansell SM, Allan J, Furman R, Aulakh S, Manochakian R, Ailawadhi S, Chanan-Khan AA, Sher T.

Br J Haematol. 2018 Aug 6. doi: 10.1111/bjh.15515. [Epub ahead of print]

PMID:
30080238
3.

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V.

Bone Marrow Transplant. 2018 Jul 9. doi: 10.1038/s41409-018-0264-8. [Epub ahead of print] Review.

PMID:
29988062
4.

Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.

Ailawadhi S, Dholaria BR, Khurana S, Sher T, Alegria V, Paulus A, Ailawadhi M, Mehta A, Chanan-Khan A, Roy V.

Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15458. [Epub ahead of print] No abstract available.

PMID:
29978498
5.

Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma.

Niazi S, Frank RD, Sharma M, Roy V, Ames S, Rummans T, Spaulding A, Sher T, Ailawadhi M, Bhatia K, Ahmed S, Tan W, Chanan-Khan A, Ailawadhi S.

Blood Adv. 2018 May 22;2(10):1120-1128. doi: 10.1182/bloodadvances.2018016717.

6.

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.

Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM.

Blood. 2018 Jul 19;132(3):293-306. doi: 10.1182/blood-2017-10-812701. Epub 2018 Apr 25.

7.

Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience.

Dholaria BR, Hammond WA, Roy V, Sher T, Vishnu P, Soyano A, Finn LE, Tun H.

Leuk Lymphoma. 2018 Mar 23:1-4. doi: 10.1080/10428194.2018.1452220. [Epub ahead of print] No abstract available.

PMID:
29566563
8.

Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.

Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, Khera N, Hashmi S, Advani P, Swaika A, Paulus A, Aslam N, Sher T, Roy V, Colon-Otero G, Chanan-Khan A.

Cancer. 2018 Apr 15;124(8):1710-1721. doi: 10.1002/cncr.31237. Epub 2018 Jan 23.

PMID:
29360160
9.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.

Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ.

Blood. 2017 Sep 7;130(10):1198-1204. doi: 10.1182/blood-2017-05-782961. Epub 2017 Jul 6.

10.

Stem cell transplantation for immunoglobulin light chain amyloidosis.

Sher T, Gertz MA.

Curr Probl Cancer. 2017 Mar - Apr;41(2):129-137. doi: 10.1016/j.currproblcancer.2017.03.001. Epub 2017 Mar 16. Review.

PMID:
28457657
11.

Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA.

Mayo Clin Proc. 2017 Apr;92(4):578-598. doi: 10.1016/j.mayocp.2017.01.003. Epub 2017 Mar 11. Review.

12.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB.

JAMA Oncol. 2017 Sep 1;3(9):1257-1265. doi: 10.1001/jamaoncol.2016.5763. Review.

13.

Post-Transplant Lymphoproliferative Disorder Presenting as CD20-Negative Plasmablastic Lymphoma in the Lung.

Kaleem T, Crozier JA, Menke DM, Sher T.

Rare Tumors. 2016 Sep 5;8(3):6220. eCollection 2016 Sep 5.

14.

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.

Sher T, Fenton B, Akhtar A, Gertz MA.

Blood. 2016 Oct 13;128(15):1987-1989. Epub 2016 Aug 19. No abstract available.

15.

Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.

Sher T, Dispenzieri A, Gertz MA.

Biol Blood Marrow Transplant. 2016 May;22(5):796-801. doi: 10.1016/j.bbmt.2015.10.010. Epub 2015 Oct 22. Review.

16.

Antibody based immunotherapy for multiple myeloma: it's about time.

Sher T, Gertz MA.

Leuk Lymphoma. 2016 Feb;57(2):269-275. doi: 10.3109/10428194.2015.1092530. Epub 2015 Dec 16.

PMID:
26373636
17.

Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review.

Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly K, Chanan-Khan A, Ailawadhi S.

Clin Lymphoma Myeloma Leuk. 2015 Oct;15(10):578-85. doi: 10.1016/j.clml.2015.06.005. Epub 2015 Jun 19.

PMID:
26198444
18.

Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.

Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Advani P, Ailawadhi S, Sher T, Linder S, Chanan-Khan A.

Br J Haematol. 2015 May;169(3):377-90. doi: 10.1111/bjh.13304. Epub 2015 Feb 17.

19.

Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type.

Swaika A, Menke DM, Jain MK, Sher T.

Ann Hematol. 2015 May;94(5):895-6. doi: 10.1007/s00277-014-2253-3. Epub 2014 Nov 15. No abstract available.

PMID:
25394720
20.

Pathophysiology and treatment of cardiac amyloidosis.

Gertz MA, Dispenzieri A, Sher T.

Nat Rev Cardiol. 2015 Feb;12(2):91-102. doi: 10.1038/nrcardio.2014.165. Epub 2014 Oct 14. Review.

PMID:
25311231

Supplemental Content

Loading ...
Support Center